Skip to content

METTL3 mediated m6A methylation of E2F2 targets MCU to promote malignant phenotype in gastric cancer cells

METTL3 mediated m6A methylation of E2F2 targets MCU to promote malignant phenotype in gastric cancer cells

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127302
Enrollment
Unknown
Registered
2026-06-29
Start date
2025-07-20
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary malignant tumor of the stomach

Interventions

Patients with primary malignant gastric tumors:None

Sponsors

The First Hospital of Hunan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. The tumor was diagnosed as a primary malignant tumor of the stomach by histopathological assessment and reviewed by experienced pathologists; 2. The patients were newly diagnosed and had not received any preoperative radiotherapy or chemotherapy; 3. The patients had complete clinical data and pathological immunohistochemical results.

Exclusion criteria

Exclusion criteria: 1. Patients with severe liver and kidney dysfunction, hematological diseases, acute and chronic infectious diseases or combined malignant tumors; 2. Patients who have gastrectomy or lymph node dissection in the past.

Design outcomes

Primary

MeasureTime frame
METTL3;E2F2 mRNA;MCU expression level;Mitochondrial biofunction;

Countries

China

Contacts

Public ContactLiu Huan

The First Hospital of Hunan University of Chinese Medicine

120812828@qq.com+86 731 89669022

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026